Matteo Levisetti
Technik-/Wissenschafts-/F&E-Leiter bei CUE BIOPHARMA, INC.
Vermögen: 15 045 $ am 31.05.2024
Ursprung des Netzwerks ersten Grades von Matteo Levisetti
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 18 | |
| Subsidiary | Biotechnology | 7 | |
Pritzker School of Medicine
4
| College/University | Other Consumer Services | 4 |
DNAtrix, Inc.
 DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX.
2
| Holding Company | Electronic Equipment/Instruments | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Matteo Levisetti
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
| IMMUNITYBIO, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| POSEIDA THERAPEUTICS, INC. | Biotechnology | Chairman Investor Relations Contact | |
| SANGAMO THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman | |
| The Johns Hopkins University | College/University | Corporate Officer/Principal Undergraduate Degree | |
Viewpoint Molecular Targeting, Inc.
 Viewpoint Molecular Targeting, Inc. Miscellaneous Commercial ServicesCommercial Services Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Conforma Therapeutics Corp.
 Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| George Washington University Law School | College/University | Graduate Degree Graduate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| CURIS, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
| IMMUNE DESIGN CORP | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| REGULUS THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Itolerance, Inc.
 Itolerance, Inc. BiotechnologyHealth Technology Itolerance, Inc. is an American biotechnology company that specializes in developing regenerative medicines. The private company was founded by Cameron Gray and is currently led by CEO Anthony J. Japour. | Biotechnology | Director/Board Member Founder | |
| FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Comptroller/Controller/Auditor | |
| University of Massachusetts | College/University | Corporate Officer/Principal Undergraduate Degree | |
| MEI PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Takeda Pharmaceuticals International, Inc.
 Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals International, Inc. provides management consulting for pharmaceutical businesses. The company is based in Deerfield, IL. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Director/Board Member | |
Genoptix, Inc.
 Genoptix, Inc. Medical SpecialtiesHealth Technology Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial, custom assay development and companion diagnostics development services. The company was founded in 1999 by Tina S. Nova and is headquartered in Carlsbad, CA. | Medical Specialties | Public Communications Contact | |
Miles, Inc.
 Miles, Inc. Chemicals: Major DiversifiedProcess Industries Part of Bayer AG, Miles, Inc. is a chemical company. The company is based in Pittsburgh, PA. | Chemicals: Major Diversified | Corporate Officer/Principal | |
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Chief Executive Officer | |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Biotechnology | Chief Executive Officer | |
January Therapeutics, Inc.
 January Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services January Therapeutics, Inc. provides biotechnology services. The company was founded by Robin Jackman and Neil Raheja and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
| MORPHOSYS AG | Biotechnology | Director/Board Member | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Chief Executive Officer | |
Xinthera, Inc.
 Xinthera, Inc. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters. | Pharmaceuticals: Major | Chief Executive Officer | |
| PERSPECTIVE THERAPEUTICS, INC. | Medical Specialties | Director/Board Member | |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Chief Operating Officer | |
| Viewpoint (US) | Director/Board Member | ||
| Indiana University | College/University | Undergraduate Degree | |
| BAYER AG | Pharmaceuticals: Major | Director/Board Member | |
| The University of Chicago | College/University | Masters Business Admin | |
Cabrellis Pharmaceuticals Corp.
 Cabrellis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ. | Pharmaceuticals: Major | Founder | |
| Coopers & Lybrand Consulting, Inc. | Corporate Officer/Principal | ||
| OWENS CORNING | Containers/Packaging | Corporate Officer/Principal | |
| Hoosier Oncology Group, Inc. | Founder | ||
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | Pharmaceuticals: Major | Director/Board Member | |
VCN Biosciences SL
 VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Miscellaneous Commercial Services | Chief Operating Officer | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 38 |
| Deutschland | 5 |
| Niederlande | 3 |
| Kanada | 2 |
| Japan | 2 |
Sektoral
| Health Technology | 35 |
| Consumer Services | 6 |
| Commercial Services | 5 |
| Process Industries | 3 |
| Finance | 2 |
Operativ
| Director/Board Member | 142 |
| Corporate Officer/Principal | 73 |
| Independent Dir/Board Member | 54 |
| Chief Executive Officer | 33 |
| Chairman | 32 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Tamar Howson | 41 |
| William Ringo | 32 |
| Bruce Carter | 25 |
| Peter Kiener | 25 |
| Fred Driscoll | 21 |
| Frank Morich | 21 |
| Stephen Dilly | 15 |
| Barry Simon | 15 |
| Chris LeMasters | 15 |
| Mark Gergen | 13 |
| Aaron Fletcher | 12 |
| Cameron Gray | 11 |
| Frank Tufaro | 11 |
| Joseph Luis Damasio | 10 |
| Claire S. Padgett | 9 |
- Börse
- Insiders
- Matteo Levisetti
- Unternehmensverbindungen
